Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GENB

Generate Biomedicines Inc

May 07 • 11:44AM ET

14.34

-0.96 -6.27 %

Healthcare • Biotechnology • USA • Small • NASD

Today, 6:40 AMGenerate Biomedicines gets FDA Fast Track for GB-4362 and posts Q1 loss of $1.07 per share

Peers: RXRX ABCL SDGR TWST BEAM

| Held by: ARKG VTI ONEQ VXF

Index	-	P/E	-	EPS (ttm)	-	Insider Own	53.26%	Shs Outstand	127.45M	Perf Week	13.54%
Market Cap	1.83B	Forward P/E	-	EPS next Y	-2.14	Insider Trans	16.07%	Shs Float	59.57M	Perf Month	20.10%
Enterprise Value	-	PEG	-	EPS next Q	-0.51	Inst Own	0.05%	Short Float	3.49%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	54.19%	Inst Trans	8.06%	Short Ratio	3.51	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-5.07%	ROA	-	Short Interest	2.08M	Perf YTD	13.36%
Book/sh	-	P/C	-	EPS next 5Y	27.44%	ROE	-	52W High	15.89 -9.73%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	11.00 30.36%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.39% 6.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.37	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	9.99%	Beta	-	Target Price	23.20
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	14.06%	Rel Volume	0.40	Prev Close	15.30
Employees	312	LT Debt/Eq	-	Earnings	Feb 25	SMA200	14.06%	Avg Volume	592.36K	Price	14.34
IPO	Feb 27, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	89,621	Change	-6.27%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Initiated	H.C. Wainwright	Buy	$16
Mar-24-26	Initiated	Piper Sandler	Overweight	$24
Mar-24-26	Initiated	Morgan Stanley	Overweight	$20
Mar-24-26	Initiated	Guggenheim	Buy	$30
Mar-24-26	Initiated	Goldman	Buy	$26
Mar-24-26	Initiated	Cantor Fitzgerald	Overweight

Today 06:24AM	Generate Biomedicines: Q1 Earnings Snapshot (Associated Press) -6.27%
06:16AM	Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update (PR Newswire)

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nally Michael	Chief Executive Officer	Mar 04 '26	Buy	12.00	20,000	240,000	572,707	Mar 06 04:55 PM
Grous Beth	Chief People Officer	Mar 02 '26	Buy	16.00	300	4,800	300	Mar 02 06:05 PM
Silvers Jason	President & CFO	Mar 02 '26	Buy	16.00	2,000	32,000	1,000	Mar 02 05:54 PM
AFEYAN NOUBAR	Director	Mar 02 '26	Buy	16.00	4,687,500	75,000,000	15,264,724	Mar 02 05:52 PM
Mendillo Jane L	Director	Mar 02 '26	Buy	16.00	1,500	24,000	1,500	Mar 02 05:47 PM
AFEYAN NOUBAR	Director	Mar 02 '26	Buy	16.00	4,687,500	75,000,000	15,264,724	Mar 02 05:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GENB

Generate Biomedicines Inc

Upgrade your Finviz experience